Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
  • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• compositions and methods are provided relating to treatment, prevention, or amelioration of one or more symptoms of broncho-constrictive disorders.
• the compositions and methods herein include formoterol, and/or a derivative thereof, and a steroid, and/or a derivative thereof.
• the compositions are propellant-free, sterile unit dose or multidose inhalation solutions intended for administration via nebulization.
• Bronchoconstrictive disorders affect millions worldwide. Such disorders include asthma (including bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness), chronic bronchitis and other chronic obstructive pulmonary diseases. Compounds having ⁇ 2 -adrenoreceptor agonist activity have been developed to treat these conditions.
• Such compounds include, but are not limited to, Albuterol (a 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol); Bambuterol (dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester); Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenylene ester); Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol); Isoproterenol (4-(1-hydroxy-2-((1-methyl-ethyl)amino)ethyl)-1,2-benzenediol); Trimetoquinol (1,2,3,4-tetrahydro
• prophylactic therapeutics for use in treatment of bronchoconstrictive disorders include steroidal anti-inflammatory agents such as beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcenolone acetonide, dexamethasone, tipredane, ciclesonid, mometasone, mometasone furoate (Asmanex® TwisthalerTM, Shering-Plough Corporation, Kenilworth, N.J.), RPR 106541, fluticasone, fluticasone propionate and budesonide. These agents can be formulated for inhalation therapy.
• BDP beclomethasone dipropionate
• BMP beclomethasone monopropionate
• flunisolide triamcenolone acetonide
• dexamethasone tipredane
• ciclesonid acetonide
• mometasone mometas
• compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided.
• the compositions provided herein are stable solutions of a bronchodilating agent, and/or a derivative thereof, and a prophylactic therapeutic agent, including, but not limited to, a steroid and/or a derivative thereof.
• the compositions are formulated in a pharmacologically suitable fluid that contains water and that are stable during long term storage.
• the compositions are suitable for direct administration to a subject in need thereof.
• Pharmacologically suitable fluids include, but are not limited to, polar fluids, including protic fluids.
• the compositions are aqueous solutions.
• compositions provided herein possess an estimated shelf-life of greater than 1, 2 or 3 months usage time at 25° C. and greater than or equal to 1, 2 or 3 years storage time at 5° C. In certain of these embodiments, using Arrhenius kinetics, >80% or >85% or >90% or >95% estimated bronchodilating agent remains after such storage. These compositions are particularly useful for administration via nebulization.
• the subject is a mammal. In other embodiments, the subject is a human.
• compositions provided herein are formulated to remain stable over a relatively long period of time.
• the compositions provided herein are stored between ⁇ 15° C. and 25C., or between 2° C. and 8° C. In one embodiment, the compositions are stored at 5° C.
• Albuterol ⁇ 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
• Bambuterol dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester
• Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenyleneester
• Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol);
• Isoproterenol (4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol); Trimetoquinol (1,2,3,
• Formoterol for use in the compositions and methods provided herein includes 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereoisomer thereof; and also includes the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
• Prophylactic therapeutics for use in the compositions and methods herein include steroidal anti-inflammatory agents, including, but not limited to, beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, rofleponide, mometasone, mometasone furoate (Asmanex® TwisthalerTM, Shering-Plough Corporation, Kenilworth, N.J.), RPR 106541, fluticasone or fluticasone propionate and budesonide, or derivatives thereof.
• the steroidal anti-inflammatory is fluticasone, fluticasone propionate, budesonide, or a derivative thereof.
• compositions are administered via nebulization.
• Administration of a nebulized aerosol is preferred over the use of dry powders for inhalation in certain subject populations, including pediatric and geriatric groups.
• compositions for use in the methods provided herein contain a pharmaceutically acceptable derivative of formoterol.
• compositions for use in the methods provided herein contain a pharmaceutically acceptable salt of formoterol.
• Pharmaceutically acceptable salts include, but are not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates and fumarates.
• the compositions for use in the methods provided herein contain formoterol fumarate or formoterol fumarate dihydrate.
• the compositions for use in the methods provided herein contain formoterol tartrate.
• compositions for use in the methods provided herein contain budesonide or fluticasone propionate.
• Compositions containing formoterol, budesonide and a fluoroalkane propellant are disclosed in U.S. Pat. No. 6,004,537.
• Compositions containing formoterol and budesonide for dry powder inhalation or metered dose inhalation are disclosed in U.S. Pat. Nos. 5,674,860 and 5,972,919. These references do not disclose the compositions provided herein that are formulated in a pharmacologically suitable fluid, as defined herein, that contains water and that are stable during long term storage.
• compositions provided herein.
• the compositions may be formulated separately or mixed in a single composition.
• the compositions contained in the combinations may be administered sequentially or intermittently.
• the compositions contained in the combinations can be mixed prior to use or can be formulated as a single composition.
• the combinations may further include a nebulizer.
• the combinations can be packaged as kits, which optionally contain other components, including instructions for use of the nebulizer and/or instructions for mixing the compositions if provided separately.
• any nebulizer is contemplated for use in the kits and methods provided herein.
• the nebulizers for use herein nebulize liquid formulations, including the compositions provided herein, containing no propellant.
• the nebulizer may produce the nebulized mist by any method known to those of skill in the art, including, but not limited to, compressed air, ultrasonic waves, or vibration.
• the nebulizer may further have an internal baffle. The internal baffle, together with the housing of the nebulizer, selectively removes large droplets from the mist by impaction and allows the droplets to return to the reservoir. The fine aerosol droplets thus produced are entrained into the lung by the inhaling air/oxygen.
• Methods for the treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders including, but not limited to, asthma, including, but not limited to, bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness; chronic bronchitis; and other chronic obstructive pulmonary diseases are provided.
• the methods involve administering an effective amount of a pharmaceutical composition provided herein to a subject in need of such treatment.
• Articles of manufacture containing packaging material, a composition provided herein, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, are also provided.
• formoterol refers to 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereoisomer thereof.
• formoterol also refers to the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
• formoterol fumarate refers to a salt of formoterol having the formula (formoterol).1 ⁇ 2 fumarate.
• Formoterol fumarate dihydrate refers to the dihydrate of formoterol fumarate.
• formoterol free base refers to the neutral, anhydrous form of formoterol.
• a composition contains, e.g., 59 ⁇ g/mL of formoterol free base means that the composition contains 59 ⁇ g/mL of neutral, anhydrous formoterol.
• Such compositions may be prepared using a derivative of formoterol.
• budesonide refers to (RS)-11 ⁇ , 16 ⁇ , 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butraldehyde.
• the term budesonide refers to the (R) isomer, the (S) isomer, and mixtures thereof.
• fluticasone refers to (6 ⁇ , 9 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-hydroxyandrosta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
• Fluticasone propionate refers to (6 ⁇ , 9 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
• an aerosol is liquid or particulate matter dispersed in air. Aerosols include dispersions of liquids, including aqueous and other solutions, and solids, including powders, in air.
• a nebulized solution refers to a solution that is dispersed in air to form an aerosol.
• a nebulized solution is a particular form of an aerosol.
• a nebulizer is an instrument that is capable of generating very fine liquid droplet for inhalation into the lung.
• the nebulizing liquid or solution is atomized into a mist of droplets with a broad size distribution by methods known to those of skill in the art, including, but not limited to, compressed air, ultrasonic waves, or a vibrating orifice.
• Nebulizers may further contain, eq., a baffle which, along with the housing of the instrument, selectively removes large droplets from the mist by impaction.
• the mist inhaled into the lung contains fine aerosol droplets.
• a pharmacologically suitable fluid is a solvent suitable for pharmaceutical use which is not a liquified propellant gas.
• exemplary pharmacologically suitable fluids include polar fluids, including protic fluids such as water.
• a combination refers to any association between two or among more items.
• fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.
• a mixture is a mutual incorporation of two or more substances, without chemical union, the physical characteristics of each of the components being retained.
• the stability of a composition refers to the length of time at a given temperature that greater than 80%, 85%, 90% or 95% of the initial amount of active ingredient, e.g., formoterol, is present in the composition.
• a composition that is stable for 30 days at 25° C. would have greater than 80%, 85%, 90% or 95% of the initial amount of active ingredient present in the composition at 30 days following storage at 25° C.
• pharmaceutically acceptable derivatives of a compound include salts, esters, enol ethers, enol esters, acids, bases, solvates, hydrates or prodrugs thereof. Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization. The compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs.
• salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and
• esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl and heterocyclyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids.
• Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of formula C ⁇ C(OR) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl ar heterocyclyl.
• enol esters include, but are not limited to, derivatives of formula C ⁇ C(OC(O)R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl ar heterocyclyl.
• Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecule, preferably 1 to about 100, more preferably 1 to about 10, most preferably one to about 2, 3 or 4, solvent or water molecules.
• Formoterol salts and hydrates are used in certain embodiments herein.
• treatment means any manner in which one or more of the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use for treating cancer.
• amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
• a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
• the pharmaceutically active compound is modified such that the active compound will be regenerated by metabolic processes.
• the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
• the compounds for use in the compositions and methods provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds for use in the compositions provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. Thus, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
• bronchoconstriction refers to a reduction in the caliber of a bronchus or bronchi.
• undesired and/or uncontrolled bronchoconstriction refers to bronchoconstriction that results in or from a pathological symptom or condition.
• Pathological conditions include, but are not limited to, asthma and chronic obstructive pulmonary disease (COPD).
• Pathological symptoms include, but are not limited to, asthma and COPD.
• a composition is stable during “long term storage” means that the composition is suitable for administration to a subject in need thereof when it has an estimated shelf-life of greater than 1, 2 or 3 months usage time at 25° C. and greater than or equal to 1, 2 or 3 years storage time at 5° C.
• Arrhenius kinetics >80% or >85% or >90% or >95% estimated bronchodilating agent remains after such storage.
• Formoterol (2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide) is derived from adrenaline and, as noted above, is used as a ⁇ 2 -stimulator in inhalation therapy of respiratory diseases, particularly for the treatment of bronchial asthma. It has been reported that in patients with reversible obstructive respiratory diseases, formoterol has a bronchodilatory effect. This effect has a relatively rapid onset (approximately 1-3 minutes) and a relatively long duration (greater than 12 hours). Formoterol inhibits the release of leukotrienes and other messenger substances involved with inflammation, such as histamines. In addition, formoterol may bring about a hyperglycaemic activity.
• formoterol has been formulated as a dry powder and administered via devices such as the Turbuhaler® and the Aerolizer®. See, e.g., Seberova et al. (2000) Respir. Med. 94(6):607-611; Lotvall et al. (1999) Can. Respir. J. 6(5):412-416; Campbell et al. (1999) Respir. Med. 93(4):236-244; Nightingale et al. (1999) Am. J. Respir. Crit. Care Med. 159(6):1786-1790; Lecaillon et al. (1999) Eur. J. Clin. Pharmacol. 55(2):131-138; Bartow et al.
• Formoterol is also available as a tablet and a dry syrup in certain areas of the world (e.g., Atock®, marcketed by Yamanouchi Pharmaceutical Co. Ltd., Japan). Formoterol formulations are also available in other areas (e.g., Europe and U.S.) for propellant-based metered dose inhalers and dry powder inhalers (e.g., Turbuhaler®, Aerolizer® and Foradil Aerolizer®). None of these formulations are water based. Sterile, stable, aqueous based inhalation solutions of formoterol for nebulization are not available, nor have they been reported.
• compositions containing formoterol in combination with other active ingredients have been disclosed. See, e.g., U.S. Pat. Nos. 5,668,110, 5,683,983, 5,677,280 and 5,654,276 (formoterol and IL-5 inhibitors), 6,136,603 (formoterol and antisense modulators of IL-5), U.S. Pat. No. 5,602,110 (formoterol and milrinone), U.S. Pat. No. 5,525,623 (formoterol and a tryptase inhibitor), U.S. Pat. Nos.
• compositions containing formoterol have been disclosed in U.S. Pat. Nos. 5,677,809, 6,126,919, 5,733,526, 6,071,971, 6,068,833, 5,795,564, 6,040,344, 6,041,777, 5,874,481, 5,965,622 and 6,161,536.
• U.S. Pat. No. 6,150,418 discloses a “liquid active substance concentrate” containing formoterol in the form of its free base or in the form of one of the pharmacologically acceptable salts or addition products (adducts) thereof as active substance.
• This “liquid active substance concentrate” is reported to be a concentrated (i.e., greater than 10 mg/mL, preferably 75 to 500 mg/mL) solution or suspension that is stable for a period of several months possibly up to several years without any deterioration in the pharmaceutical quality. This patent teaches that it is the high concentration that allows for the stability of the concentrate.
• the “liquid active substance concentrate” is not suitable for direct administration to a subject.
• U.S. Pat. No. 6,040,344 discloses an aqueous aerosol formulation of formoterol tartrate for use in a nebulizer. This patent states that the formulation disclosed therein is not attractive for long term storage.
• Budenoside and Fluticasone Propionate Budesonide, (RS)-11 ⁇ , 16 ⁇ , 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with butraldehyde, is an anti-inflammatory, synthetic corticosteroid.
• Fluticasone propionate, (6 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester is a synthetic fluorinated corticosteroid, and is known for topical dermatologic use.
• Topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
• corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of prostaglandins and leukotrienes by inhibiting the release of arachidonic acid.
• compositions containing a ⁇ 2 -adrenoreceptor agonist and a steroid for administration via nebulization are provided.
• the compositions are sterile filtered and filled in vials, including unit dose vials providing sterile unit dose formulations which are used in a nebulizer and suitably nebulized.
• Each unit dose vial is sterile and is suitably nebulized without contaminating other vials or the next dose.
• the bulk sterile formulation is sterilized by steam, gamma radiation or is prepared using sterile steroidal powder.
• the unit dose vials are formed in a form-fill-seal machine or by any other suitable method known to those of skill in the art.
• the vials may be made of plastic materials that are suitably used in these processes.
• plastic materials for preparing the unit dose vials include, but are not limited to, low density polyethylene, high density polyethylene, polypropylene and polyesters.
• the plastic material is low density polyethylene.
• the ⁇ 2 -adrenoreceptor agonist in formoterol or a pharmaceutically acceptable derivative thereof.
• the formoterol for use in the compositions provided herein is formoterol fumarate.
• Formoterol refers to 2-hydroxy-5-((1RS)-1-hydroxy-2-(((1RS)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide; or a stereo-isomer thereof.
• formoterol also refers herein to the single enantiomers 2-hydroxy-5-((1S)-1-hydroxy-2-(((1S)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide and 2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(p-methoxyphenyl)-1-methylethyl)amino)ethyl)formanilide.
• the compositions contain, in addition to a steroidal anti-inflammatory agent, including, but not limited to, budesonide and fluticasone propionate, formoterol free base at a concentration of about 5 ⁇ g/mL to about 2 ⁇ g/mL. In other embodiments, the maximum concentration of formoterol free base in the compositions is 1.5 ⁇ g/mL. In further embodiments, the concentration of formoterol free base in the compositions is about 10 ⁇ g/mL to about 1mg/mL, or about 50 ⁇ g/mL to about 200 ⁇ g/mL.
• a steroidal anti-inflammatory agent including, but not limited to, budesonide and fluticasone propionate
• the compositions contain formoterol fumarate at a concentration of about 80 ⁇ g/mL up to about 175 to 200 ⁇ g/mL. In further embodiments, the compositions contain formoterol fumarate at a concentration of about 90 ⁇ g/mL up to about 125 to 150 ⁇ g/mL.
• the formoterol fumarate is formulated, in certain compositions provided herein, at a concentration of about 100 ⁇ g/mL.
• the formoterol fumarate is formulated, in other compositions provided herein, at a concentration of about 85 ⁇ g/mL or about 170 ⁇ g/mL.
• the formoterol fumarate is formulated for single dosage administration via nebulization at a concentration of about 100 ⁇ g/mL.
• the compositions contain formoterol free base at a concentration of about 40 to about 150 ⁇ g/mL, particularly about 59 or about 118 ⁇ g/mL.
• compositions provided herein further contain, in addition to a ⁇ 2 -adrenoreceptor agonist, including formoterol, a seroidal anti-inflammatory agent, including, but not limited to, budesonide or fluticasone propionate.
• a ⁇ 2 -adrenoreceptor agonist including formoterol
• a seroidal anti-inflammatory agent including, but not limited to, budesonide or fluticasone propionate.
• Budesonide is (RS)-11 ⁇ , 16 ⁇ , 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butraldehyde.
• Budesonide also refers to the (R) isomer, the (S) isomer, and mixtures thereof.
• Fluticasone propionate refers to (6 ⁇ , 11 ⁇ , 16 ⁇ , 17 ⁇ )-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester.
• the compositions contain budesonide or fluticasone propionate at a concentration of about 5 ⁇ g/mL to about 2 mg/mL. In another embodiment, the compositions contain budesonide at a concentration of about 75 ⁇ g/mL to about 500 ⁇ g/mL, or about 125 ⁇ g/mL to about 500 ⁇ g/mL. In certain embodiments, the compositions contain budesonide at a concentration of about 125 ⁇ g/mL or 250, ⁇ g/mL.
• compositions contain fluticasone propionate at a concentration of about 75 ⁇ g/mL to about 1000 ⁇ g/mL, or about 250 ⁇ g/mL to about 1000 ⁇ g/mL. In further embodiments, the compositions contain fluticasone propionate at a concentration of about 125 ⁇ g/mL or about 250 ⁇ g/mL.
• compositions are formulated as solutions or suspensions with a pharmacologically suitable fluid.
• Pharmacologically suitable fluids include, but are not limited to, polar solvents, including, but not limited to, compounds that contain hydroxyl groups or other polar groups.
• solvents include, but are not limited to, water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
• Polar solvents also include protic solvents, including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture thereof.
• protic solvents including, but not limited to, water, aqueous saline solutions with one or more pharmaceutically acceptable salt(s), alcohols, glycols or a mixture thereof.
• particularly suitable salts are those which display no or only negligible pharmacological activity after administration.
• the compositions have a pH of about 2.0 to about 8.0.
• the particular pH of a given composition for long term storage provided herein may be determined empirically using standard stability assays well known to those of skill in the art (see, e.g., the Examples).
• the compositions have a pH of about 4.0 to about 6.0, or about 4.5 to about 5.5.
• the compositions are formulated at a pH of about 4, 4.4 or 4.6 up to about 5.5, 5.7 or 6.
• the pH is about 5.0. It has been found herein that the rate constant for decomposition of an aqueous solution of formoterol is dependent on pH.
• the rate constant (k obs ) at 60° C. at a pH of 3, 4, 5 and 7 is approximately 0.62, 0.11, 0.044 and 0.55 day 31 1 , respectively. Therefore, the decomposition of formoterol in aqueous solution at 60° C. at a buffer concentration of 5 mM and an ionic strength of 0.05 is slowest at a pH of about 5.0.
• the solubility of formoterol in aqueous solution has been found herein to be dependent on pH.
• the aqueous solubility of formoterol at ambient temperature is approximately 2.2 mg/mL.
• the aqueous solubility of formoterol at ambient temperature is approximately 3 mg/mL, while at a pH of about 3, the aqueous solubility of formoterol at ambient temperature is about 4.8 mg/mL.
• the solubility of formoterol in pure water, for example, high performance liquid chromatography (HPLC) water, at ambient temperature is approximately 2 mg/mL.
• compositions further contain a buffer, including, but not limited to, citric acid/phosphate, acetate, barbital, borate, Britton-Robinson, cacodylate, citrate, collidine, formate, maleate, Mcllvaine, phosphate, Prideaux-Ward, succinate, citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES (2-(N-morpholino)ethanesulfonic acid), BIS-TRIS (bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane), ADA (N-(2-acetamido)-2-iminodiacetic acid), ACES (N-(carbamoylmethyl)-2-aminoethanesulfonaic acid), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), MOPSO (3-(N-morpholino)-2-hydroxy
• the buffer is citric acid/phosphate buffer, acetate buffer, citrate buffer or phosphate buffer. In another embodiment, the buffer is a citrate buffer (citric acid/sodium citrate).
• the buffer concentration has been found herein to affect the stability of the composition. Buffer concentrations for use herein include from about 0 or 0.01 mM to about 150 mM, or about 1 mM to about 20 mM. In one embodiment, the buffer concentration is about 5 mM. In another embodiment, the buffer concentration is about 1 mM to about 50 mM, or about 20 mM. The kinetic-pH profile of formoterol is dependent on buffer concentration.
• the ionic strength of the compositions provided herein also has been found herein to affect the stability of the composition.
• Ionic strengths of the compositions provided herein are from about 0 to about 0.4, or from about 0.05 to about 0.16.
• Compositions having a lower ionic strength exhibit improved stability over formulations having higher ionic strength.
• the rate constant of decomposition was essentially the same at ionic strength 0.05 to 0.1, but increased to some extent at ionic strength of 0.2.
• the particular ionic strength of a given composition for long term storage provided herein may be determined empirically using standard stability assays well known to those of skill in the art (see, e.g., the Examples).
• tonicity adjusting agents may be added to provide the desired ionic strength.
• Tonicity adjusting agents for use herein include those which display no or only negligible pharmacological activity after administration. Both inorganic and organic tonicity adjusting agents may be used in the compositions provided herein.
• Tonicity adjusting agents include, but are not limited to, ammonium carbonate, ammonium chloride, ammonium lactate, ammonium nitrate, ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium tartrate, boric acid, calcium chloride, calcium disodium edetate, calcium gluconate, calcium lactate, citric acid, dextrose, diethanolamine, dimethylsulfoxide, edetate disodium, edetate trisodium monohydrate, fluorescein sodium, fructose, galactose, glycerin, lactic acid, lactose, magnesium chloride, magnesium sulfate, mannitol, polyethylene glycol, potassium acetate, potassium chlorate, potassium chloride, potassium iodide, potassium nitrate, potassium phosphate, potassium sulfate, proplyene glycol, silver nitrate, sodium acetate, sodium bicarbonate, sodium biphosphate,
• the tonicity adjusting agent is sodium chloride, which is present at a concentration of from about 0 mg/mL to about 10, 15 or 20 mg/mL.
• the compositions contain sodium chloride at a concentration of from about 0 mg/mL to about 7.5 mg/mL.
• the compositions contain sodium chloride at a concentration of 0 mg/mL, 1.5 mg/mL, 6.8 mg/mL or 7.5 mg/mL.
• the pharmacologically suitable fluid is aqueous saline.
• compositions stored at a lower temperature exhibit improved stability over formulations stored at higher temperatures.
• the estimated shelf-life of formoterol in the compositions provided herein is significantly greater than that reported for known formoterol compositions.
• the estimated shelf-life of formoterol in the compositions provided herein is about 6.2 years at 5° C. and about 7.5 months at 25° C.
• the estimated formoterol concentrations in the compositions provided herein as a function of storage time at 5° C and usage time at 25° C. was determined. It is estimated that greater than 90% of the initial formoterol present in the composition remains after 3 months of usage time at 25° C. and 3 years of storage time at 5° C. as well as after 0.5 months of usage time at 25° C. and 1 year of storage time at 5° C.
• compositions provided herein are prepared containing formoterol fumarate at a nominal concentration of 0.1 mg/mL at the indicated pH and citric acid/phosphate buffer concentrations.
• the solutions were stored at 60° C.
• formoterol is relatively more stable at a pH from about 4 to about 5, and is also more stable at lower buffer concentration.
• compositions provided herein also may include excipients and additives.
• the particular excipient or additive for use in the compositions for long term storage provided herein may be determined empirically using methods well known to those of skill in the art (see, e.g., the Examples).
• Excipients and additives are any pharmacologically suitable and therapeutically useful substance which is not an active substance. Excipients and additives generally have no pharmacological activity, or at least no undesirable pharmacological activity.
• the excipients and additives include, but are not limited to, surfactants, stabilizers, complexing agents, antioxidants, or preservatives which prolong the duration of use of the finished pharmaceutical formulation, flavorings, vitamins, or other additives known in the art.
• Complexing agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt, citric acid, nitrilotriacetic acid and the salts thereof.
• the complexing agent is EDTA.
• the complexing agent is sodium edetate.
• the compositions contain sodium edetate at a concentration of about 0.05 mg/mL to about 0.5 mg/mL, or about 0.1 mg/mL to about 0.2 mg/mL.
• Preservatives include, but are not limited to, those that protect the solution from contamination with pathogenic particles, including benzalkonium chloride or benzoic acid, or benzoates such as sodium benzoate.
• Antioxidants include, but are not limited to, vitamins, provitamins, ascorbic acid, vitamin E or salts or esters thereof.
• the compositions contain vitamin E TPGS (d- ⁇ -tocopheryl polyethylene glycol 1000 succinate).
• vitamin E TPGS is present at a concentration of about 0 mg/mL to about 100 mg/mL, or about 5 mg/mL to about 50 mg/mL.
• the compositions contain vitamin E TPGS at a concentration of 10 mg/mL, 20 mg/mL, 30 mg/mL or 50 mg/mL.
• compositions provided herein also may include a cosolvent, which increases the solubility of additives or the active ingredient(s).
• a cosolvent which increases the solubility of additives or the active ingredient(s).
• the particular cosolvent for use in the compositions for long term storage provided herein may be determined empirically using methods well known to those of skill in the art (see, eq., the Examples).
• Cosolvents for use herein include, but are not limited to, hydroxylated solvents or other polar solvents, such as alcohols such as isopropyl alcohol, glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, and polyoxyethylene alcohols.
• the compositions contain a glycol.
• the compositions contain propylene glycol and/or polyethylene glycol, including polyethylene glycol 400.
• the glycol is present at a concentration of 5 about 0 mg/mL to about 100 mg/mL, or about 5 mg/mL to about 50 mg/mL.
• the compositions contain propylene glycol at a concentration of 17 mg/mL or 20 mg/mL.
• the compositions contain polyethylene glycol 400 at a concentration of 10 mg/mL, 20 mg/mL, 30 mg/mL or 50 mg/mL.
• compositions provided herein may also contain one or more emulsifiers.
• Emulsifiers for use herein include, but are not limited to, polyoxyetheylene sorbitan fatty esters or polysorbates, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; lecithins; alginic acid; sodium alginate; potassium alginate; ammonium alginate; calcium alginate; propane-1,2-diol alginate; agar; carrageenan; locust bean gum;
• the emulsifier(s) is (are) a polyoxyetheylene sorbitan fatty ester or polysorbate, including, but not limited to, polyethylene sorbitan monooleate (Polysorbate 80), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polyoxyethylene (20) sorbitan mono-oleate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate; sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan mono-oleate; or sorbitan monopalmitate.
• the emulsifier(s) is (are) polysorbate 80, sorbitan monolaruate or polyoxyethylene (20) sorbitan nmonolaurate.
• Formoterol may be prepared according to the method disclosed in U.S. Pat. No. 3,994,974. Briefly, 4-benzyloxy-3-nitro- ⁇ -bromoacetophenone is reacted with N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amine to form the a-aminoacetophenone.
• This compound was subjected to the following series of reactions: (i) reduction of the ketone with sodium borohydride; (ii) reduction of the nitro group with aqueous hydrochloric acid and iron powder; (iii) amine formulation with acetic anhydride and formic acid; and (iv) catalytic reduction over 10% palladium on carbon to afford formoterol free base. Crystallization of the 1 ⁇ 2 fumarate salt from ethanol provides (formoterol).1 ⁇ 2 fumarate.
• reaction of optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy- ⁇ -methyl-N-(phenylmethyl)benzeneethanamine, followed by debenzylation affords the desired enantiomer of formoterol.
• Debenzylation may be accomplished by reduction with hydrogen gas in the presence of a noble metal catalyst, such as palladium on carbon.
• the required optically pure 4-benzyloxy-3-formamidostyrene oxide may be prepared from 4-benzyloxy-3-nitro- ⁇ -bromoacetophenone by (i) reduction with vorane in the presence of an optically pure aminoindanol, (ii) hydrogenation over platinum oxide catalyst, (iii) formulation with formic acid and acetic anhydride, and (iv) epoxide formation in the presence of potassium carbonate.
• the required optically pure 4-methoxy- ⁇ -methyl-N-(phenylmethyl)-benzeneethanamine may be prepared from 4-methoxyphenylacetone by (i) reductive amination with benzylamine in the presence of hydrogen and a platinum catalyst, and (ii) crystallization of the desired optically pure amine from the resulting racemic mixture as its mandelic acid salt.
• Budesonide may be synthesized by the procedure disclosed in U.S. Pat. No. 3,929,768. Briefly, reaction of triamcinolon with propionaldehyde and catalyic perchloric acid in dry dioxane at ambient temperature provides, following chromatography on hydroxy-propylated, cross-linked dextran gel, budesonide.
• Fluticasone propionate may be synthesized by the procedure disclosed in U.S. Pat. No. 4,335,121. Briefly, the corresponding carbothioic acid is prepared from the carboxylic acid precursor by reaction with dimethylthiocarbamoyl chloride in the presence of triethylamine. Reaction with bromochloromethane and sodium hydrogen carbonate in dimethylacetamide affords the corresponding S-chloromethyl carbothioate. This compound is treated with sodium iodide in acetone to give the corresponding S-iodomethyl carbothioate. Fluoride substitution of the iodo group is accomplished by reaction with silver fluoride in acetonitrile to afford the desired compound.
• compositions provided herein are prepared by procedures well known to those of skill in the art.
• a solution formulations may be prepared by the procedure of EXAMPLE 1. Briefly, polyethylene glycol 400 and/or propolyene glycol, and a preservative, such as vitamin E TPGS, are mixed at about 42° C. until a homogeneous solution forms. The temperature is lowered and the steroidal anti-inflammatory agent is added. In a second vessel, formoterol fumarate dihydrate and the remaining ingredients are dissolved in approximately 70% water. The two solutions are mixed and the resulting solution is diluted with water to the desired volume.
• Suspension formulations are prepared by the procedure of EXAMPLE 2. Briefly, all ingredients other than the steroidal anti-inflammatory agent and formoterol fumarate dihydrate are dissolved in about 40% water with mixing. The steroidal anti-inflammatory agent, which is micronized, is dispersed in the above mixture with high speed homogenization. Formoterol fumarate dihydrate is dissolved in 50% water and added to the steroidal suspension with mixing until a uniform suspension forms.
• compositions provided herein are used for treating, preventing, or ameliorating one or more symptoms of a bronchoconstrictive disorders in a subject.
• the method includes administering to a subject an effective amount of a composition containing a ⁇ 2 -adrenoreceptor agonist, including, but not limited to, formoterol, and a steroidal anti-inflammatory agent, including, but not limited to, budesonide and fluticasone propionate, whereby the disease or disorder is treated or prevented, or one or more symptoms are ameliorated.
• the subject treated is, in certain embodiments, a mammal. In certain of these embodiments, the mammal is a human.
• the method provided herein includes oral administration of a composition provided herein.
• the composition is directly administered to a subject in need of such treatment via nebulization without dilution or other modification of the composition prior to administration.
• the methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders further include administering one or more of (a), (b) or (c) as follows: (a) a ⁇ 2 -adrenoreceptor agonist; (b) a dopamine (D 2 ) receptor agonist; or (c) an anti-cholinergic agent; simultaneously with, prior to or subsequent to the composition provided herein.
• ⁇ 2 -Adrenoreceptor agonists for use in combination with the compositions provided herein include, but are not limited to, Albuterol ( ⁇ 1 -(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol); Bambuterol (dimethylcarbamic acid 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,3-phenylene ester); Bitolterol (4-methylbenzoic acid 4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-1,2-phenylene ester); Broxaterol (3-bromo- ⁇ -(((1,1-dimethylethyl)amino)methyl)-5-isoxazolemethanol); Isoproterenol (4-(1-hydroxy-2-( (1-methylethyl)amino)ethyl)
• Dopamine (D 2 ) receptor agonists include, but are not limited to, Apomorphine ((r)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol); Bromocriptine ((5′ ⁇ )-2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′, 18-trione); Cabergoline ((8 ⁇ )-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)ergoline-8-carboxamide); Lisuride (N′-((8 ⁇ )-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea); Pergolide ((8 ⁇ )-8-((methylthio)methyl)-6-propyler
• Anticholinergic agents for use herein include, but are not limited to, ipratropium bromide, oxitropium bromide, atropine methyl nitrate, atropine sulfate, ipratropium, belladonna extract, scopolamine, scopolamine methobromide, homatropine methobromide, hyoscyamine, isopriopramide, orphenadrine, benzalkonium chloride, tiotropium bromide and glycopyrronium bromide.
• the compositions contain an anticholinergic agent, such as ipratropium bromide or tiotropium bromide, at a concentration of about 5 ⁇ g/mL to about 5 mg/mL, or about 50 ⁇ g/mL to about 200 ⁇ g/mL.
• the compositions for use in the methods herein contain an anticholinergic agent, including ipratropium bromide and tiotropium bromide, at a concentration of about 83, ⁇ g/mL or about 167 ⁇ g/mL.
• IL-5 inhibitors such as those disclosed in U.S. Pat. Nos. 5,668,110, 5,683,983, 5,677,280 and 5,654,276; antisense modulators of IL-5 such as those disclosed in U.S. Pat. No. 6,136,603; milrinone (1,6-dihydro-2-methyl-6-oxo-[3,4′-bipyridine]-5-carbonitrile); milrinone lactate; tryptase inhibitors such as those disclosed in U.S. Pat. No. 5,525,623; tachykinin receptor antagonists such as those disclosed in U.S. Pat. Nos.
• leukotriene receptor antagonists such as montelukast sodium (Singular®, R-(E)1-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]-propyl]thiolmethyl]cyclopropaneacetic acid, monosodium salt), 5-lypoxygenase inhibitors such as zileuton (Zyflo®, Abbott Laboratories, Abbott Park, Ill.), and anti-IgE antibodies such as Xolair® (recombinant humanized anti-IgE monoclonal antibody (CGP 51901; IGE 025A; rhuMAb-E25), Genentech, Inc.).
• the bronchoconstrictive disorder to be treated, prevented, or whose one or more symptoms are to be ameliorated is associated with asthma, including, but not limited to, bronchial asthma, allergic asthma and intrinsic asthma, e.g., late asthma and airway hyper-responsiveness; and, particularly in embodiments where an anticholinergic agent is used, other chronic obstructive pulmonary diseases (COPDs), including, but not limited to, chronic bronchitis, emphysema, and associated cor pulmonale (heart disease secondary to disease of the lungs and respiratory system) with pulmonary hypertension, right ventricular hypertrophy and right heart failure.
• COPD chronic obstructive pulmonary diseases
• COPD chronic obstructive pulmonary diseases
• compositions provided herein are intended for administration to a subject in need of such treatment via nebulization.
• Nebulizers that nebulize liquid formulations containing no propellant are suitable for use with the compositions provided herein.
• Nebulizers are available from, e.g., Pari GmbH (Starnberg, Germany), DeVilbiss Healthcare (Heston, Middlesex, UK), Healthdyne, Vital Signs, Baxter, Allied Health Care, Invacare, Hudson, Siemens, Aerogen, Omron, Bremed, AirSep, Luminscope, Medisana, Mountain Medical, Aerosol Medical Ltd. (Colchester, Essex, UK), AFP Medical (Rugby, Warwickshire, UK), Bard Ltd.
• Nebulizers for use herein include, but are not limited to, jet nebulizers (optionally sold with compressors), ultrasonic nebulizers, and others.
• Exemplary jet nebulizers for use herein include Pari LC plus/ProNeb, Pari LC plus/ProNeb Turbo, Pari LC plus/Dura Neb 1000 & 2000, Pari LC plus/Walkhaler, Pari LC plus/Pari Master, Pari LC star, Omron CompAir XL Portable Nebulizer System (NE-C18 and JETAir Disposable nebulizer), Omron CompAir Elite Compressor Nebulizer System (NE-C21 and Elite Air Reusable Nebulizer), Pari LC Plus or Pari LC Star nebulizer with Proneb Ultra compressor, Pulmo-aide, Pulmo-aide LT, Pulmo-aide traveler, Invacare Passport, Inspiration Healthdyne 626, Pulmo-Neb Traver
• Exemplary ultrasonic nebulizers for use herein include MicroAir, UltraAir, CompAir, Pulmosonic, Scout, 5003 Ultrasonic Neb, 5110 Ultrasonic Neb, 5004 Desk Ultrasonic Nebulizer, Mystique Ultrasonic, Siemens Ultra Nebulizer 145, Luminscope's Ultrasonic Nebulizer, Medisana Ultrasonic Nebulizer, Microstat Ultrasonic Nebulizer, and MABISMist Hand Held Ultrasonic Nebulizer.
• nebulizers for use herein include 5000 Electromagnetic Neb, AeronebTM Partable Nebulizer System, AerodoseTM Inhaler, 5001 Electromagnetic Neb 5002, Rotary Piston Neb, Lumineb I Piston Nebulizer 5500, and AeroEclipse Breath Actuated Nebulizer.
• compositions provided herein may be packaged as articles of manufacture containing packaging material, a composition provided herein, which is useful for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction, and a label that indicates that the composition is used for treatment, prevention or amelioration of one or more symptoms of diseases or disorders associated with undesired and/or uncontrolled bronchoconstriction.
• the articles of manufacture provided herein contain packaging materials.
• Packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558 and 5,033,252.
• Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
• compositions are packaged with a nebulizer for direct administration of the composition to a subject in need thereof.
• Polyethylene glycol 400 and/or propylene glycol and vitamin E TPGS were mixed in a stainless steel container with heating at about 42° C. until a homogeneous liquied formed. While maintaining the liquid phase, the temperature was lowered and the steroid active ingredient, e.g., budesonide or fluticasone propionate, was added. The nixing was contiued untila all of the drug substance had dissolved. In another container all other ingredients, including formoterol fumarate dihydrate, were mixed with about 70% water until a clear solution formed. The two solutions were mixed together until a homogeneous clear solution formed. The volume was made up with water and the solution was mixed to give the desired composition.
• the steroid active ingredient e.g., budesonide or fluticasone propionate
• Fluticasone propionate/Formoterol solution formulations Concentration Ingredient Low strength High strength Formoterol fumarate 85 ⁇ g/mL 170 ⁇ g/mL dihydrate Fluticasone 125 ⁇ g/mL 250 ⁇ g/mL propionate Vitamin E TPGS 30 mg/mL 50 mg/mL Either: Propylene glycol 17 mg/mL 20 mg/mL or Polyethylene glycol 30 mg/mL 50 mg/mL 400 Citrate buffer 5 mM 5 mM Sodium Chloride 1.5 mg/mL 0 mg/mL Water q.s. q.s.
• Budesonide/Formoterol suspension formulations Ingredient Concentration Formoterol fumarate dihydrate 5-2000 ⁇ g/mL or 50-200 ⁇ g/mL Budesonide 125-500 ⁇ g/mL Disodium edetate 0.1-0.2 mg/mL Polysorbate 80 0.2-0.3 mg/mL Sodium chloride 5-10 mg/mL Citrate buffer 1-20 mM Water q.s.
• Fluticasone propionate/Formoterol suspension formulations Ingredient Concentration Formoterol fumarate dihydrate 5-2000 ⁇ g/mL or 50-200 ⁇ g/mL Fluticasone propionate micronized 250-1000 ⁇ g/mL Sorbitan monolaurate 0.05-0.2 mg/mL Polyoxyethylene 20 sorbitan 0.1-0.3 mg/mL monolaurate Sodium chloride 5-10 mg/mL Citrate buffer 1-20 mM Water q.s.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Dispersion Chemistry (AREA)
• Otolaryngology (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=26962701

Family Applications (6)

Family Applications After (5)

Country Status (10)

Cited By (11)

Families Citing this family (66)

Citations (23)

Family Cites Families (115)

• 2001
  • 2001-06-22 US US09/887,496 patent/US20030055026A1/en not_active Abandoned
• 2002
  • 2002-03-01 WO PCT/US2002/006252 patent/WO2002083113A2/fr active IP Right Grant
  • 2002-03-01 CA CA2444535A patent/CA2444535C/fr not_active Expired - Lifetime
  • 2002-03-01 AU AU2002250199A patent/AU2002250199B2/en not_active Expired
  • 2002-03-01 EP EP02719098.2A patent/EP1385494B1/fr not_active Expired - Lifetime
  • 2002-03-01 PT PT2719098T patent/PT1385494T/pt unknown
  • 2002-03-01 JP JP2002580917A patent/JP4580145B2/ja not_active Expired - Lifetime
  • 2002-03-01 SI SI200231075A patent/SI1385494T1/sl unknown
  • 2002-03-01 ES ES02719098.2T patent/ES2572973T3/es not_active Expired - Lifetime
  • 2002-05-13 US US10/145,978 patent/US20020183293A1/en not_active Abandoned
• 2004
  • 2004-06-19 HK HK04104465.4A patent/HK1061523A1/zh not_active IP Right Cessation
• 2009
  • 2009-06-24 JP JP2009149871A patent/JP2009235089A/ja not_active Withdrawn
  • 2009-11-24 US US12/625,328 patent/US8623851B2/en not_active Expired - Lifetime
• 2010
  • 2010-01-22 US US12/692,095 patent/US20100120734A1/en not_active Abandoned
• 2011
  • 2011-03-21 US US13/052,792 patent/US8716348B2/en not_active Expired - Fee Related
• 2013
  • 2013-12-27 US US14/142,178 patent/US9597396B2/en not_active Expired - Lifetime

Patent Citations (25)

Also Published As

Similar Documents

Legal Events